Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative ClaimsPublished: April 3rd 2025 | Updated:
- Resource Utilization With Insulin Pump Therapy for Type 2 Diabetes Mellitus
Published: December 21st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
2
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
3
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
4
Mediterranean Diet Improves Psoriasis Severity, Study Finds
5
